medigraphic.com
ISSN 2954-3835 (Electronic)
ISSN 2683-2828 (Print)

2020, Number S3

<< Back Next >>

Cardiovasc Metab Sci 2020; 31 (S3)

Brief annotations on cytokine release syndrome and interleukin-6 therapeutic blockage in SARS-CoV-2/COVID-19

Amezcua-Guerra LM

Language: Spanish
References: 13
Page: 255-258
PDF size: 166.52 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Worldometer. Coronavirus cases. Worldometer. doi: 10.1101/2020.01.23.20018549V2.

  2. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 Mar 3. doi: 10.1007/s00134- 020-05991-x. [Epub ahead of print]

  3. Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D’Cruz DP, Shoenfeld Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Medicine. 2013; 11 (1): 185.

  4. La Rosée P, Horne AC, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019; 133 (23): 2465-2477.

  5. Strippoli R, Caiello I, De Benedetti F. Reaching the threshold: a multilayer pathogenesis of macrophage activation syndrome. J Rheumatol. 2013; 40 (6): 761-767.

  6. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014; 66 (9): 2613-2620.

  7. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020; 368 (6490): 473-474.

  8. Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting interleukin-6 signaling in clinic. Immunity. 2019; 50 (4): 1007-1023.

  9. Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016; 8 (8): 959-970.

  10. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497-506.

  11. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H et al. Clinical and immunologic features in severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130 (5): 2620-2629.

  12. Effective Treatment of Severe COVID-19 Patients with tocilizumab [Internet]. ChinaXiv [fecha de publicación: 3 de mayo de 2020]. Disponible en: http://www.chinaxiv.org/abs/202003.00026

  13. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395 (10229): 1033-1034.




2020     |     www.medigraphic.com